Results 161 to 170 of about 7,704 (220)

Cutting through the stones: Unlocking therapeutic potential with gene editing tools for primary hyperoxaluria type 1. [PDF]

Mol Ther
Schneller J, Du W, Ding H.
europepmc   +1 more source

Efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria: A systematic review and meta-analysis of randomized controlled trials. [PDF]

Indian J Urol
Khan U, Mubariz M, Rezq H, Mahmoud A, Moiz Nasir M, Ul Ain N, Bazai UK, Khan MZ, Abuelazm M.   +8 more
europepmc   +1 more source

How We Treat Primary Hyperoxaluria Type 1. [PDF]

Clin J Am Soc Nephrol
Breeggemann MC, Harris PC, Lieske JC, Tasian GE, Wood KD.   +4 more
europepmc   +1 more source

Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1. [PDF]

Drugs
Kang C.
europepmc   +1 more source

Lumasiran: A Review in Primary Hyperoxaluria Type 1. [PDF]

Drugs
Kang C.
europepmc   +1 more source

Synthesis and hLDHA Inhibitory Activity of New Stiripentol-Related Compounds of Potential Use in Primary Hyperoxaluria. [PDF]

Int J Mol Sci
Rico-Molina M, Ortega-Vidal J, Molina-Canteras J, Cobo J, Altarejos J, Salido S.   +5 more
europepmc   +1 more source

Human glyoxylate metabolism revisited: New insights pointing to multi-organ involvement with implications for siRNA-based therapies in primary hyperoxaluria. [PDF]

J Inherit Metab Dis
Wanders RJA, Groothoff JW, Deesker LJ, Salido E, Garrelfs SF.   +4 more
europepmc   +1 more source

Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption. [PDF]

Mol Ther
Jiang Y, Chen S, Hsiao S, Zhang H, Xie D, Wang ZJ, Ren W, Liu M, Liao J, Wu Y.   +9 more
europepmc   +1 more source

4-hydroxy-2-oxoglutarate metabolism in a mouse model of Primary Hyperoxaluria Type 3. [PDF]

Biochem Biophys Rep
Li X, Cunneely OP, Fargue S, Wood KD, Assimos DG, Knight J.   +5 more
europepmc   +1 more source